EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small-Cell Lung Cancer: TORG2241 (UBE-Q)

Shinji Nakamichi, Kaoru Kubota, Kotone Matsuyama, Toshihiro Misumi, Toshiyuki Kozuki, Shunichi Sugawara, Katsuhiko Naoki, Nobuaki Kobayashi, Takehito Shukuya, Tsuneo Shimokawa, Masashi Ishihara, Hiroshi Wakui und 11 weitere

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2023.09.006 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Shinji Nakamichi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Squamous Cell, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Nippon Kayaku.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: According to the results of the KEYNOTE-407 trial, pembrolizumab plus platinum-based chemotherapy is the standard of care for patients with previously untreated advanced squamous non-small-cell lung cancer (NSCLC). Ubenimex, a potent aminopeptidase inhibitor, is an oral drug with immunostimulatory and antitumor activities. We aim to assess the safety and efficacy of ubenimex in combination with pembrolizumab, nab-paclitaxel, and carboplatin in patients with previously untreated advanced squamous NSCLC. PATIENTS AND METHODS: This prospective, single-arm, multicenter, phase II clinical trial is conducted to confirm the tolerability and efficacy of the tested drugs. Patients with previously untreated advanced squamous NSCLC will receive a predetermined daily dose of ubenimex orally plus 4 cycles of pembrolizumab, nab-paclitaxel, and carboplatin, followed by continuous administration of ubenimex and pembrolizumab for a maximum of 2 years. To confirm tolerability, the daily dose of ubenimex will begin at level 1 (30 mg), which will be increased to levels 2 (60 mg) and 3 (120 mg) according to the escalation criteria, with a standard 3 + 3 design for achieving the target dose-limiting toxicity rate of 33%. The efficacy, safety, and tolerability of ubenimex at the determined dose level will be analyzed. The primary endpoint of the efficacy evaluation will be the objective response rate assessed by an independent review committee. CONCLUSIONS: This is the first study to evaluate the efficacy and safety of ubenimex combined with pembrolizumab, nab-paclitaxel, and carboplatin in patients with previously untreated advanced squamous NSCLC. The results will help devise future treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCarcinoma, Squamous CellAntibodies, Monoclonal, HumanizedHumansCarboplatinProspective StudiesAntineoplastic Combined Chemotherapy ProtocolsPaclitaxelAlbuminsLeucine

Stichwörter der Autor:innen

CarboplatinNab-paclitaxelPembrolizumabSquamous non-small cell lung cancerUbenimex

Substanzen

130-nm albumin-bound paclitaxelCarboplatinpembrolizumabubenimexPaclitaxelAlbuminsLeucineAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.
  • Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan. Electronic address: kkubota@nms.ac.jp.
  • Department of Health Policy and Management, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.
  • Department of Biostatistics, Yokohama City University School of Medicine, Yokohama-shi, Kanagawa, Japan.
  • Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan.
  • Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai-shi, Miyagi, Japan.

Förderung

  • Nippon Kayaku

Zitieren

APA

Nakamichi, S., Kubota, K., Matsuyama, K., Misumi, T., Kozuki, T., Sugawara, S., Naoki, K., Kobayashi, N., Shukuya, T., Shimokawa, T., Ishihara, M., Wakui, H., Hosomi, Y., Tanaka, H., Saito, H., Hosokawa, S., Takiguchi, Y., Kasai, T., Nokihara, H., …, & Okamoto, H. (2024). A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small-Cell Lung Cancer: TORG2241 (UBE-Q). Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2023.09.006

Vancouver

Nakamichi S, Kubota K, Matsuyama K, Misumi T, Kozuki T, Sugawara S, et al. A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small-Cell Lung Cancer: TORG2241 (UBE-Q). Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2023.09.006

BibTeX
@article{Nakamichi2024,
  author = {Nakamichi, Shinji and Kubota, Kaoru and Matsuyama, Kotone and Misumi, Toshihiro and Kozuki, Toshiyuki and Sugawara, Shunichi and Naoki, Katsuhiko and Kobayashi, Nobuaki and Shukuya, Takehito and Shimokawa, Tsuneo and Ishihara, Masashi and Wakui, Hiroshi and Hosomi, Yukio and Tanaka, Hiroshi and Saito, Haruhiro and Hosokawa, Shinobu and Takiguchi, Yuichi and Kasai, Takashi and Nokihara, Hiroshi and Morita, Ryo and Aono, Hiromi and Furuya, Naoki and Okamoto, Hiroaki},
  title = {A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small-Cell Lung Cancer: TORG2241 (UBE-Q)},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2023.09.006}
}
Kostenlos starten →